Skip to content
Trial Eligibility
Menu

A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors

NCT07940881

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

The objective of the study is to evaluate the safety and tolerability of SI-B037 in participants with locally advanced or metastatic solid tumors.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Locally Advanced /Metastatic Solid Tumors
  • Locally Advanced / Metastatic Solid Tumors
  • First in Human
  • Metastatic Solid Cancers
  • Non Small Cell Lung Cancer
  • NSCLC
  • Lung Cancer (Diagnosis)
  • Lung Cancer (NSCLC)
  • Lung Cancer (Non-Small Cell)
  • Lung Cancer (Locally Advanced or Metastatic)
  • Melanoma (Skin Cancer)
  • Ovarian Cancer
  • Phase 1
  • Phase 1 Clinical Trial
  • Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC)

Eligibility basics and study details

Study type
Interventional
Phase
Phase 1
Ages
18 years and older
Sex
All
Healthy volunteers
Not accepted
Sponsor
SystImmune Inc.
Last updated on ClinicalTrials.gov
November 17, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Texas · 1

  • NEXT Oncology · Houston, TX

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.